Baltimore, USA - 01 Sep `17Early Molecular Changes After NB-UVB

Official Title: Early Molecular Changes in Vitiligo After Narrowband Ultraviolet Therapy

In Brief: This is an investigator-initiated, single-blinded, ascending dose study of NB-UVB treatment for vitiligo in adults of 3 treatments for one week. It is designed to measure the molecular changes and re-pigmentation in affected and normal skin of participants with vitiligo and normal skin in healthy participants. Participants diagnosed with vitiligo who are enrolled in the study will receive phototherapy (NB-UVB), with the starting dose of 250 mJ/cm2. The dose will be increased by 10% with each treatment. Small skin samples will be collected before and after NB-UVB treatment.

Ages Eligible: 18 Years to 100 Years

Start Date: September 1, 2017 

Completion Date (estimated): September 1, 2022

Status: Active, recruiting

Study ID from ClinicalTrials.gov: NCT03270241

Location: Johns Hopkins Outpatient Center, Baltimore, Maryland, United States, 21287

Contact: To learn more about this study, you or your doctor may contact Ruizhi Wang by phone +1-410-502-7546 or email CTReP@jhmi.edu. Please refer to this study by its NCT number.

FAQOther Questions

  • Vitiligo and hearing loss: any connection?

    In short, NO. Recent research shows no relationship between a degree of skin depigmentation and hearing loss severity in vitiligo patients. The results of this study showed tha...

  • What is vitiligo?

    Vitiligo (pronounced vit-ill-EYE-go) is a relatively common skin disease characterized by smooth, white, painless spots or patches on various parts of the body and hairs above i...

  • How long does it take to treat vitiligo?

    Treatment results will vary by person and type of vitiligo. The rule of thumb is that you will need to allow at least 3 to 6 months before you begin to see results from any trea...